Ignt

[mickymoose99]

Ingen Signs 5-Month IR/PR Deal With the Money Channel


Statement by the Chairman

YUCAIPA, Calif., Oct 8, 2009 (GlobeNewswire via COMTEX) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading Global Medical Device manufacturer focused in the $ 4 Billion Respiratory Market for the growing ageing and emerging markets for Home (DME), Hospital and Aviation Industries announced today that the company has signed a national 5 month campaign with The Money Channel and American Scene Radio program to reach millions of wealthy investors.
The Money Channel offers Ingen major exposure to the investment world. The program includes 12 Investor Showcase Radio segments on the American Scene radio program from now through March 31, 2010. Ingen will also be present at the World Money Show in February-2010 which will be a televised segment on Fox Business Television.

The Money Channel is one of the most successful, national Money-talk Radio programs in America. "Steve Crowley's American Scene" was launched from the Disney/MGM Radio Studios at the Walt Disney World Resort in June 1990. American Scene attracts a larger and larger radio audience every month from coast to coast. The Money Channel recently added Boston and Atlanta affiliates to our tremendous national lineup of stations. Today, The Money Channel has a national base of 3,000,000 listeners on a three-hour daily radio broadcast through the mighty IRN/USA Radio Network affiliates, plus other affiliates, and they have a growing listening audience on the Internet worldwide. This is the primary destination for Steve Crowley's insights and advice in the financial world. Plus Steve interviews all the top experts, analysts, money managers and authors covering stocks, investments, business, the economy and trends, Small-Cap CEOs and much more. More than 200 Financial "Stars" are interviewed in constant rotation....from Steve Forbes to Tobin Smith to Beth Dater to Joe Battipaglia. No other Money-talk Radio Program in America even comes close to this level of credible content.

"I have worked with Steve Crowley over the past several years, and The Money Channel and American Scene Radio have been very effective in the ability to introduce Ingen Technologies to a large group of wealthy investors. Ingen is performing very well with sales, operations, and projected growth trends. The company is at its reflex point, and projections for 2010 include revenues over $10M, several new Oxyview products, a decrease in manufacturing costs and an increase in margins, as well as an increase in earnings," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.

The Money Channel // American Scene Radio // WallStreetCast

Ingen Technologies,Inc. - Home

About Ingen:

Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.

The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc.

Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

This news release was distributed by GlobeNewswire, GlobeNewswire - Press Release Distribution - EDGAR Filings - Video News Releases

SOURCE: Ingen Technologies, Inc.


By Staff

CONTACT: CONTACT: Ingen Technologies, Inc.
Jeff Morgan
909-790-7180
info@ingen-tech.com
Ingen Technologies,Inc. - Home

(C) Copyright 2009 GlobeNewswire, Inc. All rights reserved.
-0-

INDUSTRY KEYWORD: Healthcare & Medical Services
SUBJECT CODE: HEALTH
Business Contracts

[mickymoose99]

IGNT
Starting to heat up +16%
RSI Line is @ 42.72 curving up looking good
volume is moving should go over the 10 day avg of 56 million as of now its at 55 million
bids are building .0028 as of now
staring to heat up,

[mickymoose99]

Wall Street News Alert: Stock on the Move: -- November 3, 2009

Weston, FLA, Nov 03, 2009 (M2 PRESSWIRE via COMTEX) -- Wall Street News Alert's "stocks to watch" this morning , Ingen Technologies, Inc.



Ingen Technologies, Inc. (OTC: IGNT) up 32% on 89.4 million shares traded.

On Nov 2, 2009 Ingen Technologies, Inc. recently announced that the CEO, Scott Sand, will discuss conservative projections for 2010 tomorrow, Tuesday November 3, 2009, at 11:24AM on The Money Channel's American Scene Radio with host Steve Crowley.

A growing elderly population, increase in home oxygen therapy and surgeries and an increase in Chronic Obstructive Pulmonary Diseases in the USA will result in demand for better efficiency and cost reductions in medical care. The elderly population in the USA age 75 and older in 2010 is expected to be almost 19M. In 2015 it is expected to increase to 20M and over the next 30 years will more than double. The Oxyview and Oxyview Nasal Cannula improves home oxygen therapy and reduces supplier costs by decreasing unnecessary service calls, thus reducing government expenditures related to treating COPD.

[mickymoose99]

MY LITTLE BIRD JUST FLEW BACK FROM ignt WINDOWS HE SAID POSS BIG NEWS COMING AT THE CLOSE

[mickymoose99]

Ingen Announces Projections of $10M in Sales for 2010

YUCAIPA, Calif., Nov 3, 2009 (GlobeNewswire via COMTEX) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that the CEO, Scott Sand, discussed conservative projections for 2010 on The Money Channel's American Scene Radio with host Steve Crowley this past Tuesday.
A growing elderly population, increase in home oxygen therapy and surgeries, and an increase in Chronic Obstructive Pulmonary Diseases in the USA will result in demand for better efficiency and cost reductions in medical care. The elderly population in the USA age 75 and older in 2010 is expected to be almost 19M. In 2015 it is expected to increase to 20M, and over the next 30 years will more than double. The Oxyview and Oxyview Nasal Cannula improves home oxygen therapy and reduces supplier costs by decreasing unnecessary service calls, thus reducing government expenditures related to treating COPD.

The World Health Organization (WHO) estimates that COPD as a single cause of death in the world shares 4th and 5th places with HIV/AIDS (after coronary heart disease, cerebrovascular disease and acute respiratory infection). COPD is the fourth leading cause of death in the U.S. and is projected to be the third leading cause of death for both males and females by the year 2020. It is estimated that there may currently be 16 million people in the United States currently diagnosed with COPD, and that there may be as many as an additional 14 million or more in the United States still undiagnosed, as they are in the beginning stages and have little to minimal symptoms and have not sought health care yet. About 1.5 million emergency department visits by adults 25 and older were made for COPD in 2000. The total estimated cost of COPD in 2002 was $32.1 billion. $18 billion were direct costs. $14.1 billion were indirect cost, and it is estimated that the total cost of managing COPD in 1998, physicians, medications, hospital and nursing care, etc., exceeded 15 billion dollars in the United States.

With proper marketing, advertising, branding, distribution and direct sales, Ingen expects to generate $10M in sales. These numbers are based on assumptions and recent historical trends with the company's increase in sales and market acceptance. The ISO 13485 Certification expected in December-2009 will instantly result in large export shipments of the Oxyview and Oxyview Nasal Cannula products. In addition, the company has signed marketing contracts with various firms to activate an immediate direct sales program to oxygen providers, suppliers and COPD support groups in the USA. The sales in 2010 will represent approximately less than 1% of the US market in oxygen cannula sales.

With the new manufacturing revisions, manufacturing costs will decrease approximately by 50%, while this new revision increases quality and efficiency in the manufacture of Oxyview and the Oxyview Nasal Cannula. The prior sales margins of 63% will remain the same while the company passes these manufacturing savings directly to its distribution as an incentive to better compete with the competition.

"With the new auditors in place, and near completion of the required SEC filings, the management is focused in increasing sales and distribution of the Oxyview and Oxyview Nasal Cannula; while we continue to finalize ISO and GSA in the next 2 months. The GSA application was submitted in September-2009 and GSA has informed us that they have undergone internal changes and would respond in the next 30 days. GSA increases our sales in to the VA hospitals, while the ISO certification opens huge doors for exporting our products globally," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.

Welcome

U.S. Senior Population Projections by Age (2010-2050) - Bar Charts - Swivel

COPD Statistics

Ingen Technologies,Inc. - Home

About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adults, children and infants. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufactures all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.

The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc.

Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

This news release was distributed by GlobeNewswire, GlobeNewswire - Press Release Distribution - EDGAR Filings - Video News Releases

SOURCE: Ingen Technologies, Inc.


By Staff

CONTACT: CONTACT: Ingen Technologies, Inc.
Jeff Morgan
909-790-7180
Ingen Technologies,Inc. - Home

(C) Copyright 2009 GlobeNewswire, Inc. All rights reserved.
-0-

INDUSTRY KEYWORD: Healthcare & Medical Services
SUBJECT CODE: MEDICAL
Company Announcement

[mickymoose99]

Ingen Receives $100K Purchase Order Today for New Oxyview Nasal Cannula


Sales and Demand for New Products Continue to Increase
YUCAIPA, Calif., Nov 4, 2009 (GlobeNewswire via COMTEX) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that the company has received a purchase order from MedOx Corporation for 40,000 new Oxyview Nasal Cannulas in value of $100,000.
A growing elderly population, increase in home oxygen therapy and surgeries, and an increase in Chronic Obstructive Pulmonary Diseases in the USA has resulted in an increase of buyers for Ingen's new Oxyview Nasal Cannula. The company now provides 8 different models of the Oxyview and Oxyview Nasal Cannula. The cannulas are designed for Adults, Pediatrics and Infants, and include 0-6 liters/minute and a low-flow 0-3 liters/minute unit that is either reusable or comes attached to a high quality 7' latex free oxygen tube with a curved soft-tip nasal cannula. The Oxyview Nasal Cannula is the only oxygen cannula in the world with a flow meter built-in that provides extremely accurate flow rate readings for the patient and caregiver.

The company also received very good news today from the COPD Foundation. The November issue of COPD Digest has been printed and shipped and is receiving an excellent response at the American College of Chest Physician's Annual 2009 conference in San Diego, CHEST 2009. Ingen has a full-page color ad in this edition of the COPD Digest and telephone orders and PayPal orders have increased this week.

"We are seeing a strong increase in revenues, and expect this trend to continue over the next several years. Our accountants and auditors are diligently working on completion of the SEC filings, specifically the 10-KSB. We anticipate filing a revised annual and quarterly report on the OTC Pink Sheets later next week. The company is progressing forward very nicely at this time and we will continue to make public announcements as each event occurs," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.

Oxyview Nasal Cannula - Home

CHEST 2009 :: Program Highlights

Ingen Technologies,Inc. - Home

About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 billion in the US, and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing US and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adult, children and infants. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch, as it manufacturers all of its respiratory products in the United States. There are 32 million US patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide, according to the World Health Organization. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.

The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc.

Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

This news release was distributed by GlobeNewswire, GlobeNewswire - Press Release Distribution - EDGAR Filings - Video News Releases

SOURCE: Ingen Technologies, Inc.

[mickymoose99]

IGNT moving on the ask .
volume 64 million and is over the ten day avg
RSI LINE is the same at 44.60 but starting to show a nice curve
MACD is even
keep your eye on it , getting into good position
COULD BE LOOKING AT A NICE JUMP

[mickymoose99]

Related Quotes
Symbol Price Change
IGNT.PK 0.0018 0.0000


{"s" : "ignt.pk","k" : "c10,l10,p20,t10","o" : "","j" : ""} Press Release Source: Ingen Technologies, Inc. On Wednesday January 20, 2010, 8:15 am EST

YUCAIPA, Calif., Jan. 20, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading manufacturer of respiratory medical devices, recently announced that the current quarter sales represented an increase of 17.7% from sales in the quarter ended November 30, 2008. Sales were sparked by the introduction of Oxyview Nasal Cannula unit that includes a cannula with Ingen’s Oxyview unit. Additional capital also enabled the company to increase the advertising and marketing of the Oxyview products. Ingen anticipates that the sales of Oxyview will increase from the current quarter’s sales as the Company expands its sales channels.



The total cost of sales for the quarter ended November 30, 2009 has a gross margin of 90.8%. The reported cost of sales for the quarter ended November 30, 2008 had a gross margin of 89.4%. The Company anticipates that its gross margin will continue to stay in the range of the current quarter.



The largest components of Ingen’s SG&A are advertising, legal and professional services, travel associated with both sales and business development, outside services and salaries. The advertising expense increased from zero in the quarter ended November 30, 2008 to $41,090 in the quarter ended November 30, 2009. The Company expects to continue advertising at current levels as it continues to promote Oxyview.



The Company has reduced its debt to the note holders by $2.3M, and expects to reduce the entire balance by March-2010. The company anticipates a share buy-back program for all of its shareholders once the note is paid in full.



The company projects that the Oxyview Nasal Cannula will bring $10M in revenues, and the new Oxyview Pulse Oximeter an additional $1M in revenues in 2010.



Ingen Technologies,Inc. - Home


About Ingen:



Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and a successful registration with the Food & Drug Administration. The company has domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009 the Oxyview Nasal Cannula was introduced as the world's first oxygen cannula with an in-line pneumatic oxygen flow meter. In 2010 the company introduced the Oxyview Pulse Oximeter. The Oxyview product line is available to the home care markets, commercial medical markets, aviation, automotive, and government sources. The company is licensed with the Department of Health and Human Services, and manufactures its products in the State of California. With approximately 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide, Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.



The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc.



Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company’s progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management’s opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company’s operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company’s periodic filings with the U.S. Securities and Exchange Commission.

[mr_fanstockstic]

A Short PR This Morning,

Ingen Opens Doors With Hospital Purchases

The Company Signs a Contract for MediGroup GPO Proposal
YUCAIPA, Calif., Jan 21, 2010 (GlobeNewswire via COMTEX) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading manufacturer of respiratory medical devices, recently announced that it has received several bulk purchases from various hospitals around the country. Columbia Memorial Hospital submitted a bulk purchase order for the new Oxyview Pulse Oximeter, and this is a strong indication of increased sales for 2010.
On January 14, 2010, the company received a purchase order from the Oregon based Columbia Memorial Hospital for the new Oxyview Pulse Oximeter. The Company has signed a contract with MediGroup to develop various GPO proposals and will move forward this quarter to align strategic national GPO contracts with the hospital industry.

"We look forward to working with Andy Klearman, President of MediGroup. This group was brought to the table by Charles Vorwaller, one of our Board of Directors. We expect to sell all of our products to hospitals, and MediGroup has the expertise to develop this distribution channel for the company," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.

Medigroup Services, Savings & Solutions

MedOx Corporation - Welcome

Oxyview Nasal Cannula - About Us - Yucaipa, CA

Ingen Technologies,Inc. - Home

[cleare39]

Ingen Opens Doors With Hospital Purchases
The Company Signs a Contract for MediGroup GPO Proposal

YUCAIPA, Calif., Jan 21, 2010 (GlobeNewswire via COMTEX) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading manufacturer of respiratory medical devices, recently announced that it has received several bulk purchases from various hospitals around the country. Columbia Memorial Hospital submitted a bulk purchase order for the new Oxyview Pulse Oximeter, and this is a strong indication of increased sales for 2010.
On January 14, 2010, the company received a purchase order from the Oregon based Columbia Memorial Hospital for the new Oxyview Pulse Oximeter. The Company has signed a contract with MediGroup to develop various GPO proposals and will move forward this quarter to align strategic national GPO contracts with the hospital industry.
"We look forward to working with Andy Klearman, President of MediGroup. This group was brought to the table by Charles Vorwaller, one of our Board of Directors. We expect to sell all of our products to hospitals, and MediGroup has the expertise to develop this distribution channel for the company," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.